Objectives: The aim was to investigate the relationship between HDL and the risk of developing any type of malignancy, AIDSdefining malignancies (ADM) or non-AIDS-defining malignancies (NADM) in a cohort of HIV-infected patients. Methods: Patients from the Icona Foundation Study with at least one HDL value per year since enrolment up to June 2015 were included. HDL values were categorized as low (< 39 mg/dl in males or < 49 mg/dl in females) or normal. To evaluate factors associated with the risk of any type of malignancy, ADM and NADM, Kaplan Meier curves and Cox proportional hazards regression models were used (models included: age at enrolment, gender, smoking status, HCVAb, HBsAg, nadir CD4+, ART exposure, calendar year of enrolment, current CD4+, current HIV-RNA, current HDL-cholesterol, current triglycerides). Results: Among 4897 patients [13440 person-years of follow-up (PYFU)], 104 diagnoses of cancer were observed [56 ADM, 48 NADM] with an overall incidence rate of 7.7 (95% confidence interval, 6.3-9.2) per 1000/PYFU. At enrolment, patients with or without incident cancer showed significant differences in terms of age (years) [median (IQR): 45(37-53) vs 37(31-45), p< 0.0001], nadir CD4+ (cells/mm3) [179(66-277) vs 324 (190-457), p< 0.0001], CD4+ (cells/mm3) [220 (85-472) vs 407 (237-580), p< 0.0001], HDL (mg/dl) [35(28-46) vs 40 (33-49), p=0.001] and cal(only variables significantly associated with the considered outcomes were reported). Conclusion: In addition to well known risk factors, low HDL is an independent predictor of developing any type of malignancy or NADM. Its role in NADM pathogenesis needs to be elucidated.

Low High-density Lipoprotein Cholesterol (HDL) is Associated with the Risk of Non-AIDS Defining Malignancies / Squillace N; Galli L; Bandera A; Castagna A; Madeddu G; Caramello P; Antinori A; Cattelan AM; Maggiolo F; Cingolani A; Gori A; d'Arminio Monforte A; ICONA Foundation Study. - (2015). ((Intervento presentato al convegno 15th European AIDS Conference tenutosi a Barcellona nel 21-24 October 2015.

Low High-density Lipoprotein Cholesterol (HDL) is Associated with the Risk of Non-AIDS Defining Malignancies

MADEDDU, Giordano;
2015

Abstract

Objectives: The aim was to investigate the relationship between HDL and the risk of developing any type of malignancy, AIDSdefining malignancies (ADM) or non-AIDS-defining malignancies (NADM) in a cohort of HIV-infected patients. Methods: Patients from the Icona Foundation Study with at least one HDL value per year since enrolment up to June 2015 were included. HDL values were categorized as low (< 39 mg/dl in males or < 49 mg/dl in females) or normal. To evaluate factors associated with the risk of any type of malignancy, ADM and NADM, Kaplan Meier curves and Cox proportional hazards regression models were used (models included: age at enrolment, gender, smoking status, HCVAb, HBsAg, nadir CD4+, ART exposure, calendar year of enrolment, current CD4+, current HIV-RNA, current HDL-cholesterol, current triglycerides). Results: Among 4897 patients [13440 person-years of follow-up (PYFU)], 104 diagnoses of cancer were observed [56 ADM, 48 NADM] with an overall incidence rate of 7.7 (95% confidence interval, 6.3-9.2) per 1000/PYFU. At enrolment, patients with or without incident cancer showed significant differences in terms of age (years) [median (IQR): 45(37-53) vs 37(31-45), p< 0.0001], nadir CD4+ (cells/mm3) [179(66-277) vs 324 (190-457), p< 0.0001], CD4+ (cells/mm3) [220 (85-472) vs 407 (237-580), p< 0.0001], HDL (mg/dl) [35(28-46) vs 40 (33-49), p=0.001] and cal(only variables significantly associated with the considered outcomes were reported). Conclusion: In addition to well known risk factors, low HDL is an independent predictor of developing any type of malignancy or NADM. Its role in NADM pathogenesis needs to be elucidated.
Low High-density Lipoprotein Cholesterol (HDL) is Associated with the Risk of Non-AIDS Defining Malignancies / Squillace N; Galli L; Bandera A; Castagna A; Madeddu G; Caramello P; Antinori A; Cattelan AM; Maggiolo F; Cingolani A; Gori A; d'Arminio Monforte A; ICONA Foundation Study. - (2015). ((Intervento presentato al convegno 15th European AIDS Conference tenutosi a Barcellona nel 21-24 October 2015.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11388/55209
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact